Clonidine 0.2mg Patch Oral Equivalent
A clonidine 0.2 mg/24-hour transdermal patch is approximately equivalent to oral clonidine 0.2 mg twice daily (0.4 mg total daily dose).
Dosing Conversion
According to the 2017 ACC/AHA Hypertension Guidelines, the dosing ranges are 1, 2:
- Oral clonidine: 0.1–0.8 mg/day divided into 2 doses
- Transdermal clonidine patch: 0.1–0.3 mg applied once weekly
The patch designation (e.g., "0.2 mg") refers to the amount of clonidine delivered per 24 hours, not the total drug content. For practical conversion purposes, the daily delivery rate of the patch (in mg/24 hours) approximates the total daily oral dose needed.
Conversion Algorithm:
- Identify the patch strength (mg delivered per 24 hours)
- Match to equivalent total daily oral dose (same numerical value)
- Divide oral dose into twice-daily administration (standard oral dosing frequency is BID)
For a 0.2 mg/24-hour patch:
- Total daily clonidine delivery = 0.2 mg
- Equivalent oral dose = 0.2 mg total daily = 0.1 mg twice daily
However, research suggests the conversion may not be exactly 1:1. Studies comparing transdermal and oral clonidine found that equivalent doses "on a weight basis" produced similar blood pressure effects, but plasma concentrations were more stable with transdermal delivery 3, 4. The transdermal route provides steadier drug levels without the peaks and troughs of oral dosing 4.
Clinical Considerations
Important caveats when converting:
- Start conservatively: If converting from patch to oral, consider starting with 0.1 mg BID and titrating up based on blood pressure response
- Pharmacokinetic differences: The patch provides continuous delivery over 7 days with more stable plasma levels; oral dosing creates fluctuations 4
- Withdrawal risk: Both formulations carry risk of rebound hypertension with abrupt discontinuation 1, 2. Always taper clonidine gradually rather than stopping suddenly
- Timing of conversion: When switching from patch to oral, apply the first oral dose when removing the patch, as transdermal absorption continues for several hours after removal 4
Safety Profile
The guidelines emphasize that clonidine (both formulations) is reserved as last-line therapy due to significant CNS adverse effects, especially in older adults 1, 2. Common side effects include:
- Dry mouth
- Sedation/drowsiness
- Bradycardia
- Hypotension (particularly orthostatic)
The transdermal formulation may have better tolerability with fewer CNS side effects compared to oral administration due to more stable plasma concentrations 3, 5, though local skin reactions can occur with the patch.
Practical Recommendation
For a 0.2 mg/24-hour patch, convert to oral clonidine 0.1 mg twice daily initially, with close blood pressure monitoring and potential titration to 0.2 mg twice daily if needed for adequate control. This conservative approach accounts for individual variability in absorption and response while minimizing risk of rebound hypertension or inadequate blood pressure control during the transition.